Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Purpura, Thrombocytopenic, Idiopathic × crexavibart × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Other hematologic neoplasm 1 Lymphoid 1

Conditions

Purpura, Thrombotic Thrombocytopenic 1 Purpura, Thrombocytopenic, Idiopathic 1 Neoplasms, Plasma Cell 1 Lymphoma 1 Leukemia 1 COVID-19 1

Interventions

fostamatinib 3 romiplostim 2 eltrombopag 2 ogalvibart 1 crexavibart 1 Inosine Triphosphate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05393999 2023-04-24

SABRE

Imperial College Healthcare NHS Trust

Phase 2 Withdrawn

LymphoidOther hematologic neoplasmPlasma cell

COVID-19, Leukemia, Lymphoma, Purpura, Thrombotic Thrombocytopenic, Purpura, Thrombocytopenic, Idiopathic, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡